Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 15 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Ongoing HTAs by SESCS in Spain in April 2026

In April 2026, the Canary Islands Healthcare Evaluation Service (SESCS) is working on several HTAs, including evaluations in e-health, IVD, neuromodulation, obstetrics and gynecology, and some other fields. These projects are being elaborated within the annual work plan of the Spanish Network of HTA Agencies (RedETS), financed by the Ministry of Health.

Some MedTech-related examples are provided below:

  • Telemonitoring systems for the prediction and detection of falls in people over 65 years of age;
  • Universal non-invasive prenatal screening using fetal DNA in maternal blood for the detection of aneuploidies in chromosomes 13, 18, 21, and sex chromosomes;
  • Electroconvulsive therapy (ECT) in the treatment of resistant major depressive disorder;
  • Efficacy and safety of non-pharmacological interventions in patients with fibromyalgia in primary care.

The full details in Spanish can be found hereand here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.